Elsevier

World Neurosurgery

Volume 131, November 2019, Pages 252-263.e2
World Neurosurgery

Literature Review
Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme

https://doi.org/10.1016/j.wneu.2019.07.180Get rights and content

Background

Glioblastoma (GBM) is the most common and deadly form of brain tumor. After standard treatment of resection, radiotherapy, and chemotherapy, the 5-year survival is <5%. In recent years, research has uncovered several potential targets within the Notch signaling pathway, which may lead to improved patient outcomes.

Methods

A literature search was performed for articles containing the terms “Glioblastoma” and “Receptors, Notch” between 2003 and July 2015. Of the 62 articles retrieved, 46 met our criteria and were included in our review. Nine articles were identified from other sources and were subsequently included, leaving 55 articles reviewed.

Results

Of the 55 articles reviewed, 47 used established human GBM cell lines. Seventeen articles used human GBM surgical samples. Forty-five of 48 articles that assessed Notch activity showed increased expression in GBM cell lines. Targeting the Notch pathway was carried out through Notch knockdown and overexpression and targeting δ-like ligand, Jagged, γ-secretase, ADAM10, ADAM17, and Mastermindlike protein 1. Arsenic trioxide, microRNAs, and several other compounds were shown to have an effect on the Notch pathway in GBM. Notch activity in GBM was also shown to be associated with hypoxia and certain cancer-related molecular pathways such as PI3K/AKT/mTOR and ERK/MAPK. Most articles concluded that Notch activity amplifies malignant characteristics in GBM and targeting this pathway can bring about amelioration of these effects.

Conclusions

Recent literature suggests targeting the Notch pathway has great potential for future therapies for GBM.

Introduction

Glioblastoma (GBM) is the most common and lethal form of brain tumor. In the United States, GBM incidence is approximately 3 cases per 100,000 people. The prognosis for this disease continues to be bleak, with a mean survival of only 12–15 months after diagnosis. In patients who receive the standard treatment of resection, radiation therapy, and chemotherapy, the mean 5-year survival is <5%.1, 2, 3, 4 It is therefore imperative for new treatments to be developed to increase the survival and quality of life for patients with GBM. Research in recent years has found several potential chemotherapeutic targets for GBM within the Notch receptor–mediated signaling pathway.

The Notch pathway is involved in a diverse array of cellular activities, including differentiation, proliferation, apoptosis, and cell survival. In mammals, the Notch pathway provides intercellular communication via direct cell-to-cell contact between 2 neighboring cells, which are called the signal-sending cell and the signal-receiving cell (Figure 1). The signal-sending cell expresses δ-like or Jagged ligands on its cell membrane surface, and the signal-receiving cell expresses Notch receptors on its cell membrane surface. In mammals, the Notch receptor has 4 isoforms (Notch1–4).5 Each Notch receptor is a 300-kD single-pass transmembrane protein with an intracellular domain (NICD) and an extracellular domain (NECD).6

Notch signaling is initiated by binding of one of its ligands to the NECD. On binding, the Notch receptor undergoes a conformational change that exposes site 2 of the NECD, enabling it to be cleaved by a member of the ADAM-family of metalloproteases. Cleavage of site 2 releases the NECD-ligand complex, which is endocytosed and degraded by the signal-sending cell. In the signal-receiving cell, the enzyme γ-secretase (comprised of subunits presenilin, nicastrin, PEN2, and APH1) cleaves the Notch receptor at exposed sites 3 and 4 (S3/S4) to release the NICD. The NICD then translocates to the nucleus and associates with the DNA-binding protein CSL (comprising subunits CBF1, Su(H), and LAG-1). Binding of NICD to CSL results in an NICD-CSL complex that displaces transcriptional repressors. In addition, the transcriptional coactivator, Mastermind (MAM), recognizes the NICD-CSL complex and activates the expression of several target genes, especially the hairy and enhancer-of-split (HES) and the hairy/enhancer-of-split related with YRPW motif protein (HEY) families. The HES and HEY families are transcriptional repressors deeply implicated in neurodevelopment and carcinogenesis.7, 8

Notch signaling is involved in many cellular processes, and dysregulation of the Notch gene or its signaling cascades can lead to neoplasms. Dysregulation of Notch signaling has been observed in bone marrow, lymphatic, lung, skin, breast, pancreatic, prostate, ovarian, and liver cancers.9, 10, 11, 12, 13 Aberrant Notch signaling has also been recently observed in GBM cells and is the focus of this review.

The goal of this systematic review is to determine if there is a correlation of Notch pathway activation with the development and progression of GBM and to identify possible candidate molecular targets for pharmacologic therapies in patients with GBM. We hope that the information found in this article will assist clinicians and scientists in the development of clinical trials and basic science projects targeting the Notch signaling cascade. We found that most of the literature supports the hypothesis that Notch signaling is increased in GBM and may lead to GBM neoplasia and aggressiveness.

Section snippets

Study Selection

Using the MeSH (Medical Subject Heading) database system of PubMed, a literature search was performed between 2003 and July 2015 for all articles containing the terms “glioblastoma” and “receptors, notch((“Glioblastoma”[Mesh]) AND “Receptors, notch”[Mesh])”. The articles were limited to humans as the only study species; reviews were excluded. A total of 62 articles were found from the initial screen. Nine articles were identified through additional sources. None of these were found to be

GBM Cell Types Used

Of 55 articles reviewed, 35 used only established human GBM cell lines,14, 15, 16, 17, 18, 22, 23, 25, 26, 27, 28, 30, 31, 35, 37, 38, 44, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 60, 61, 63, 64, 65, 66, 67, 68 7 used only human GBM surgical samples,19, 24, 29, 34, 43, 47, 59 10 used a combination of established human GBM cell lines and human GBM surgical samples,20, 21, 36, 39, 40, 41, 42, 45, 46, 48 2 used a rat GBM cell line along with established human GBM cell lines,32, 62 and 1 did not

Discussion

The findings of our literature review suggest that Notch pathway activation is a characteristic of GBM. This finding is consistent with previous studies that showed increased Notch activation in primary GBM compared with low-grade gliomas, secondary GBM, and normal brain tissue.40, 59, 72 Increased Notch activity was found to be associated with many of the malignant hallmarks of cancer such as self-sufficiency in growth signals, insensitivity to antigrowth signals, evasion of apoptosis,

Conclusions

The research discussed in this article suggests that Notch pathway activation is a characteristic of GBM. GBM is the most common and most aggressive primary central nervous system malignancy, with a dismal survival average of 12–15 months.2 A multitude of recent and ongoing research shows the connection between Notch signaling activation and the pathophysiology of GBM. Four clinical trials (NCT01122901, NCT01119599, NCT01269411, and NCT01189240) exploring the relationship of the Notch pathway

References (80)

  • D. Hanahan et al.

    Hallmarks of cancer: the next generation

    Cell

    (2011)
  • H. Shao et al.

    Targeting Notch signaling for cancer therapeutic intervention

    Adv Pharmacol

    (2012)
  • B.T. Tan et al.

    The cancer stem cell hypothesis: a work in progress

    Lab Invest

    (2006)
  • K.B. Pointer et al.

    Glioblastoma cancer stem cells: biomarker and therapeutic advances

    Neurochem Int

    (2014)
  • G. Iacob et al.

    Current data and strategy in glioblastoma multiforme

    J Med Life

    (2009)
  • M. Jhanwar-Uniyal et al.

    Glioblastoma: molecular pathways, stem cells and therapeutic targets

    Cancers (Basel)

    (2015)
  • D.E. Spratt et al.

    Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma

    J Neurooncol

    (2014)
  • R. Stupp et al.

    Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

    N Engl J Med

    (2005)
  • S. Artavanis-Tsakonas et al.

    Notch signaling: cell fate control and signal integration in development

    Science

    (1999)
  • S.J. Bray

    Notch signalling: a simple pathway becomes complex

    Nat Rev Mol Cell Biol

    (2006)
  • A. Gupta et al.

    Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells

    Prostate

    (2008)
  • O. Hopfer et al.

    The Notch pathway in ovarian carcinomas and adenomas

    Br J Cancer

    (2005)
  • M.E. Mullendore et al.

    Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer

    Clin Cancer Res

    (2009)
  • A. Raafat et al.

    Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh)

    Oncogene

    (2004)
  • P. Viatour et al.

    Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway

    J Exp Med

    (2011)
  • M. Kanamori et al.

    Contribution of Notch signaling activation to human glioblastoma multiforme

    J Neurosurg

    (2007)
  • W.B. Li et al.

    MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme

    Cancer Biol Ther

    (2011)
  • J. Wang et al.

    siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth

    Mol Biol Rep

    (2012)
  • X. Fan et al.

    NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts

    Stem Cells

    (2010)
  • K.E. Hovinga et al.

    Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate

    Stem Cells

    (2010)
  • M. Ying et al.

    Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells

    Stem Cells

    (2011)
  • K.J. Lim et al.

    Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and Notch signaling

    Anticancer Res

    (2012)
  • X. Gao et al.

    Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling

    J Neurooncol

    (2007)
  • M. Monticone et al.

    z-Leucinyl-leucinyl-norleucinal induces apoptosis of human glioblastoma tumor-initiating cells by proteasome inhibition and mitotic arrest response

    Mol Cancer Res

    (2009)
  • J.L. Li et al.

    DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo

    Cancer Res

    (2011)
  • J. Lin et al.

    MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme

    Cell Death Dis

    (2012)
  • A. Fassl et al.

    Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1

    Oncogene

    (2012)
  • X. Zhang et al.

    Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation

    Cancer Sci

    (2012)
  • R. Wang et al.

    Glioblastoma stem-like cells give rise to tumour endothelium

    Nature

    (2010)
  • D.H. Floyd et al.

    Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch

    Neuro Oncol

    (2012)
  • Cited by (0)

    Conflict of interest statement: The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

    View full text